Dr P.H. Andersen is managing a fund for innovative research in Denmark and was Executive Vice President and Head of Research and corporate patents and trademarks at H. Lundbeck A/S. Lundbeck is a CNS focussed Pharmaceutical Company headquartered in Copenhagen, Denmark.
Dr. Andersen was employed in Lundbeck R&D in 1999. Prior to joining Lundbeck he was Vice President and Director of Drug Discovery in Acadia Pharmaceuticals and prior to that he held various positions at Novo Nordisk from 1983-1997, latest as Corporate Project Director.
Dr. Andersen has been involved in startup of a number of biotechs in Medicon Valley over the years. Currently, he is Chairman of the Board of Directors in the Biotech Research & Innovation Centre in Copenhagen and Epitherapeutics Aps. He his member of the Board of Directors in Serendex in Copenhagen. Chair of the Research Directory Group in EFPIA and member of the Policy Group of Research and Education in the Danish Industry Association.
Dr. Andersen holds degrees in chemistry, biochemistry and medicine from University of Copenhagen.
Jasper Bos, PhD is Head of Healthcare Fund at Merck ventures, the corporate venture capital fund of Merck Serono SA, which invests in early stage and start-up biotech and pharmaceutical companies. Prior to joining Merck Serono SA, Jasper was instrumental in the founding of IFHA, a private equity fund backed by large Dutch and international institutional investors. He was instrumental in the structuring and capital raise of IFHA and negotiated and managed private equity investments in emerging economies in the healthcare and insurance sectors. Before IFHA, Jasper worked as health economics and strategy manager at the Netherlands Vaccine Institute.
Currently, he is a Member of the Board of Directors of EpiTherapeutics AS, Galecto Biotech, Neviah Genomics and an Observer to the Board of Vaximm AG. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands and has published more than 30 articles on health economics and vaccines.
François defended his PhD in 1991, at the Pasteur Institute in Paris, in the lab of François Jacob. Then, he did his Post-doc at Genentech in the US. After that, he joined the GSK Research Institute of Geneva where he worked as a scientist in CNS research until 2001. His main field of interest was to validate metabotropic Glutamate receptors for CNS diseases. Then, he left GSK to found Addex Pharmaceuticals in Geneva, where he stayed CEO until 2005. Addex is a Biotech company dedicated to the discovery of novel treatments for CNS diseases and particularly focused on the development of mGluR5 antagonists. In 2005, he worked as an acting CEO for a VC firm in three different French Biotechs, before joining Merck Serono in September 2006 as Director, Early Stage Licensing, where he managed the in-licensing of several novel preclinical programs. François is the author of more than 40 peer reviewed scientific articles and inventor in 2 patents.
Andreas Segerros joined Sunstone as partner in 2012 and focuses on therapeutics and drug delivery investments. Andreas has been working together with the Sunstone team since 2007 as a Venture Partner and has been serving as Chairman of the Sunstone Business Development Board, an external review group consisting of worldwide pharma executives, since its establishment in 2007. Andreas brings to Sunstone more than 20 years of commercial and development experience in the international pharma industry and has held a number of positions across Europe, the US and Japan. Before Sunstone, he held a position at Ferring Pharmaceuticals in Switzerland where he was Head of the Business Development Group and Operations Planning. Andreas holds a Master’s degree in Biotechnology and Biomaterials from the Royal Institute of Technology in Stockholm and an MBA from the University of Uppsala. Free time is fueled by adrenaline: sailing, running and bicycling, always with an achievement in mind.
Raúl Martín-Ruiz is an Investment Director in Ysios Capital Partners, a leading independent Spanish venture capital firm that provides private equity financing to human healthcare and life sciences companies. Prior to joining Ysios in 2008 he developed his career in Laboratorios Almirall, initially working in corporate business development (Licensing In and Licensing Out) and then as responsible for developing and managing the business of the company in the Americas and Africa through licensees and distributors. Initially he was trained as a researcher in the areas of Central Nervous System pharmacology in the Department of Pharmacology of the UPV-EHU (University of the Basque Country), and in neurochemistry in the Department of Neurochemistry of the IIBB-CSIC (Institute for Biomedical Research of Barcelona-Spanish National Research Council). He is a Member of the Board of Directors of STAT Diagnostica. He has a B.Sc. in Biological Sciences by the UPV-EHU and holds a Ph.D. in Neurosciences by the same university and the CSIC.
Marco is Partner at Forbion Capital Partners and serves on the Board of Prexton. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion Marco was Business Development Director and project manager at DSM Pharmaceutical Products. Prior to that Marco was scientist at Cytos Biotechnology in Switzerland.
After obtaining a master’s degree in molecular biology from the University of Groningen, Marco received his PhD in biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Counsil in Cambridge, UK. He currently serves on the Board of RSPR Pharma, and is Observer to the Board of Exosome Diagnostics and Oxyrane. He was instrumental in the start-up and served on the board of Dezima Pharma, which was sold to Amgen for up to USD1.5Bn in 2015. Marco also served on the Board of Akarna Therapeutics, which was sold in 2016 to Allergan for up to USD 1Bn.
Alan O’Connell is a Partner at Seroba. He has a background in product and business development in the pharma/ biotech industry. Prior to joining the firm in 2003, Alan worked in a variety of roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and he also spent time at the Medicines and Healthcare Products Regulatory Agency (London).
His previous venture capital experience was gained at Estée Lauder Investments (New York). Alan still sits on the scientific advisory board of the Lauder funded Alzheimer’s Drug Discovery Foundation.
Alan graduated with a Ph.D. (neurophamacology) from the National University of Ireland, Galway (1994) and has a Master’s degree in pharmacology from the University of London (1990). He carried out post-doctoral neuroscience research at University College, Dublin and has published in several scientific journals.
Alan sits on the boards of Ario Pharma; Crescent Diagnostics; Heart Metabolics; Opsona Therapeutics; and Veryan Medical.